Adaptimmune Therapeutics ADAPY
OTC ADAPY
$0.02 +0.00 (+0.00%)
At close: Nov 10, 2026 · 4:00 PM EST

Adaptimmune Therapeutics (ADAPY) EBITDA (2014 - 2025)

Updated

Adaptimmune Therapeutics (ADAPY) posted EBITDA of -$27.78 million for Q2 2025, compared with $71.44 million a year earlier.

Analysis

Adaptimmune Therapeutics (ADAPY) EBITDA (2014 - 2025) Analysis & Trends

For the trailing twelve months through Jun 30, 2025, EBITDA at Adaptimmune Therapeutics was -$153.59 million; for FY2024, it came in at -$57.54 million.

  • In prior years, Adaptimmune Therapeutics' EBITDA was -$129.9 million in FY2023, -$157.89 million in FY2022, -$155.68 million in FY2021 and -$125.81 million in FY2020.
  • Quarterly EBITDA has run from a low of -$70.68 million in Q4 2024 to a high of $71.44 million in Q2 2024 over five years.
  • According to Business Quant data, EBITDA for the three prior quarters was -$43.27 million (Q1 2025), -$70.68 million (Q4 2024) and -$11.86 million (Q3 2024).
Peer Set

Peer Comparison

Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -27.78 Mn
Mar 31, 2025 -43.27 Mn
Dec 31, 2024 -70.68 Mn
Sep 30, 2024 -11.86 Mn
Jun 30, 2024 71.44 Mn
Mar 31, 2024 -46.43 Mn
Dec 31, 2023 -46.99 Mn
Sep 30, 2023 -43.74 Mn
Jun 30, 2023 -42.68 Mn
Mar 31, 2023 3.50 Mn
Dec 31, 2022 -25.81 Mn
Sep 30, 2022 -41.50 Mn
Jun 30, 2022 -42.20 Mn
Mar 31, 2022 -48.39 Mn
Dec 31, 2021 -40.45 Mn
Sep 30, 2021 -40.77 Mn
Jun 30, 2021 -37.88 Mn
Mar 31, 2021 -36.59 Mn
Dec 31, 2020 -35.79 Mn
Sep 30, 2020 -34.05 Mn
API Access

Adaptimmune Therapeutics EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda&ticker=ADAPY&period=max&api_key=YOUR_API_KEY